Investing.com UK - Financial Markets Worldwide
🚀 ProPicks AI Hits +34.9% Return!Read Now

Sanofi to pay $19.8 million over claims of drug overcharges - U.S.

Published 03/04/2017, 16:30
Updated 03/04/2017, 16:41
© Reuters. A logo is seen in front of the entrance at the headquarters of French drugmaker Sanofi in Paris
SASY
-

WASHINGTON (Reuters) - Sanofi SA (PA:SASY)'s Sanofi-Pasteur unit has agreed to pay $19.8 million (15.88 million pounds) to resolve claims that it overcharged the U.S. Department of Veterans Affairs for medications between 2002 and 2011, U.S. Justice officials said on Monday.

Sanofi-Pasteur, the company's vaccine division, had told the Veterans Affairs (VA) Department in 2012 that it had made an accounting error in overcharging for certain drugs, the Justice Department said in a statement.

© Reuters. A logo is seen in front of the entrance at the headquarters of French drugmaker Sanofi in Paris

In an emailed statement, a Sanofi spokeswoman said the company "cooperated fully and negotiated in good faith with the government."

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.